Drug Trial Radar · NCT00093158
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
Last checked: Nov 19, 2026Latest source record: Aug 21, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13,800
Actual
Start
Aug 2003
Primary completion
Not stated
Study completion Jan 2007
Sponsor
- Lead sponsor
- The Medicines CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 7, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention \[PCI\]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of PCI; Arm B) provides non-inferior or superior overall clinical outcomes and 2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important secondary objective for this comparison is to show that bivalirudin is not inferior for ischemic complications.
Conditions
- Unstable Angina
- Myocardial Infarction
- Acute Disease
Interventions
Angiomax (bivalirudin) anticoagulantDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cardiovascular Research Foundation
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.